Deutsche Bank AG Decreases Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Deutsche Bank AG reduced its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 89.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 166,220 shares of the biopharmaceutical company's stock after selling 1,393,852 shares during the period. Deutsche Bank AG owned about 0.08% of Esperion Therapeutics worth $366,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Cibc World Markets Corp purchased a new stake in Esperion Therapeutics in the fourth quarter worth $39,000. Crestline Management LP purchased a new position in Esperion Therapeutics in the 4th quarter worth about $63,000. SLT Holdings LLC bought a new stake in Esperion Therapeutics during the 4th quarter valued at about $66,000. Foundations Investment Advisors LLC boosted its position in Esperion Therapeutics by 48.6% in the 4th quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company's stock valued at $66,000 after buying an additional 9,872 shares during the period. Finally, J.W. Cole Advisors Inc. purchased a new stake in Esperion Therapeutics in the 4th quarter valued at about $66,000. Hedge funds and other institutional investors own 47.39% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Needham & Company LLC reduced their target price on shares of Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. HC Wainwright restated a "buy" rating and set a $16.00 price objective on shares of Esperion Therapeutics in a report on Friday, April 25th. The Goldman Sachs Group dropped their price target on Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. Finally, JMP Securities restated a "market outperform" rating and set a $4.00 price target (down previously from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $6.25.

Esperion Therapeutics Stock Performance

NASDAQ:ESPR traded up $0.07 during trading hours on Wednesday, reaching $1.12. The company's stock had a trading volume of 5,481,030 shares, compared to its average volume of 5,449,459. The company has a market capitalization of $221.98 million, a P/E ratio of -1.75 and a beta of 0.75. Esperion Therapeutics, Inc. has a 12 month low of $0.69 and a 12 month high of $3.94. The stock has a 50 day moving average price of $0.97 and a two-hundred day moving average price of $1.72.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03). The firm had revenue of $65.00 million during the quarter, compared to analysts' expectations of $54.97 million. As a group, analysts predict that Esperion Therapeutics, Inc. will post -0.29 EPS for the current fiscal year.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.